465 related articles for article (PubMed ID: 18341596)
1. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
[TBL] [Abstract][Full Text] [Related]
2. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Rosenstock J; Baron MA; Dejager S; Mills D; Schweizer A
Diabetes Care; 2007 Feb; 30(2):217-23. PubMed ID: 17259484
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
6. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.
Bosi E; Camisasca RP; Collober C; Rochotte E; Garber AJ
Diabetes Care; 2007 Apr; 30(4):890-5. PubMed ID: 17277036
[TBL] [Abstract][Full Text] [Related]
7. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes.
Schweizer A; Couturier A; Foley JE; Dejager S
Diabet Med; 2007 Sep; 24(9):955-61. PubMed ID: 17509069
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
11. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.
Scherbaum WA; Schweizer A; Mari A; Nilsson PM; Lalanne G; Jauffret S; Foley JE
Diabetes Obes Metab; 2008 Aug; 10(8):675-82. PubMed ID: 18248490
[TBL] [Abstract][Full Text] [Related]
13. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Kothny W; Shao Q; Groop PH; Lukashevich V
Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
[TBL] [Abstract][Full Text] [Related]
14. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
15. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Bolli G; Dotta F; Rochotte E; Cohen SE
Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Iwamoto Y; Kashiwagi A; Yamada N; Terao S; Mimori N; Suzuki M; Tachibana H
Diabetes Obes Metab; 2010 Aug; 12(8):700-8. PubMed ID: 20590747
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
19. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
20. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
